

**DERMATOLOGY, VENEREOLOGY & LEPROSY**

PAPER-II

DVD/D/18/06/II

Time: 3 hours  
Max. Marks:100

**Important Instructions:**

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

**Write short notes on:**

1. A 20-year-old female presents with recurrent painful nodules associated with fever over the lower limbs of 6-month duration. 4+3+3
  - a) Enumerate the steps of evaluation of this patient.
  - b) List out the common etiological factors of this condition.
  - c) Management of this patient.
2. 2+4+4
  - a) Role of eosinophils in cutaneous diseases.
  - b) Classify cutaneous disease with eosinophilia.
  - c) Hypereosinophilic syndrome.
3. 4+4+2
  - a) Urticarial vasculitis- definition and classification.
  - b) Evaluation of a patient with suspected urticarial vasculitis.
  - c) Management of urticarial vasculitis.
4. 3+7
  - a) Syndromes associated with poikiloderma.
  - b) Dyskeratosis congenita.
5. 5+5
  - a) Premalignant skin lesions.
  - b) Epidermodysplasia verruciformis.
6. 4+3+3
  - a) Erythema annulare centrifugum.
  - b) Necrolytic migratory erythema.
  - c) Erythema gyratum repens.
7. 3+4+3
  - a) Primary Raynaud's phenomenon.
  - b) Erythromelalgia.
  - c) Management of Raynaud's phenomenon.

P.T.O

**DERMATOLOGY, VENEREOLGY & LEPROSY**

PAPER-II

- |     |  |       |
|-----|--|-------|
| 8.  | a) Telogen effluvium.<br>b) Anagen effluvium.<br>c) Loose anagen syndrome.   | 4+3+3 |
| 9.  | a) Classify and describe the bullous lesions associated with systemic lupus erythematosus.<br>b) Mention the evaluation and management of bullous SLE. | 5+5   |
| 10. | Mycophenolate mofetil:<br>a) Pharmacology and mechanism of action.<br>b) Indications, adverse effects and monitoring guidelines.                       | 5+5   |

\*\*\*\*\*